Home » Clinical Trials » Therapeutic Areas
Therapeutic Areas: Nephrology | Urology | Family Medicine
Disease Category: Benign Prostatic Hyperplasia (Enlarged Prostate)
Location: United States, IN
A Phase III multi-center prospective randomized, parallel-group, placebo-controlled, double-blind, clinical evaluation of NX-1207 for the treatment of BPH (Benign Prostatic Hyperplasia, or Enlarged Prostate)
The purpose of this study is to evaluate the efficacy and safety of NX-1207 and to see if it could be useful for men with BPH. The study treatment will consist of either an injection of NX-1207 or of a placebo into the prostate. If you end up receiving the placebo, you will be offered the chance to receive NX-1207 at the end of the study. The study will last for 12 months.
CW ID: 178190
Date Last Changed:
May 2, 2014
Debbie Johnson, CCRC, Director of ResearchFirst Urology, PSC101 Hospital Blvd.Jeffersonville, IN 47130Phone: (812) 206-8161Fax: (812) 288-2612
First Urology, PSC
If you would like to learn more about participating in this research study, please email the trial contact using the form below.
We value your privacy and your information will only be used by the research center to contact
you regarding this study.
DISCLAIMER: CenterWatch does not conduct clinical research.
CenterWatch is a publishing company that posts clinical trials information on behalf of sponsor companies,
contract research organizations, clinical research sites and other interested parties. This information
is designed to help patients find clinical trials of interest and contact the research centers
conducting the trials.
Copyright © 1995-2015 CenterWatch.